- Pharosyn has raised a $3 million seed round, led by Moonfire Ventures. The company has not disclosed its valuation.
- The research into AI hallucination mitigation conducted by one of Pharosyn’s founders while he was at Cambridge now forms the basis of reports prepared by a major pharmaceutical company.
- The time it takes Pharosyn’s tools to produce reports has been reduced from four hours to 15 minutes, which is a 94% improvement.
Pharosyn, a London-based startup that develops AI systems for the commercial departments of pharmaceutical companies, has raised $3 million in seed funding, led by Moonfire Ventures, with Entrepreneurs First, Transpose Platform, and General Advance also participating. The company has not publicly disclosed its valuation.
A funding round has taken place following a previous pre-seed investment in 2025 from the same investors, and Pharosyn is currently collaborating with a biopharmaceutical company that is among the top ten, as well as with a number of mid-sized pharmaceutical companies, on commercial and competitive intelligence. Senior directors at these companies now use Pharosyn daily to inform strategic decisions, according to the company.
“We reduced their time to produce a report or answer a question by 94%. Whereas before it was four hours to produce a report, senior executives were waiting hours and hours for an answer. We brought that down to a few minutes,” co-founder and CEO Stephen Cowley tells Tech Funding News.
Pharma companies are under pressure to make quicker decisions on pricing, market access, and portfolios as patent cliffs shorten revenue opportunities. The global AI market in pharma and biotech is expected to grow from $8.54 billion in 2026 to $154.10 billion by 2034.
Pharosyn is focusing on commercial and competitive intelligence rather than drug discovery, which has attracted most pharma AI funding this year. The company says its approach rests on the idea that pharma companies need custom AI infrastructure embedded directly inside commercial teams, rather than generic tools, to keep a competitive edge.
Born out of Cambridge research on hallucinations
Cowley and his co-founder Joshua Hampson met at the University of Cambridge, where Cowley studied artificial intelligence and Hampson focused on biochemistry, both graduating in the top 5% of their cohorts.
Cowley’s Cambridge research, titled “Mitigating Hallucinations in LLMs,” addressed the challenge of preventing large language models from generating inaccurate information. He says this research is now integrated into Pharosyn’s product.
The founders first used their system in a single consultancy. Last year, they began working directly with pharmaceutical teams in oncology, neurology, immunology, and rare diseases. The wider team includes engineers with backgrounds in AI-driven financial forecasting and enterprise software, alongside consultants with senior experience in pharmaceutical commercial strategy at Citeline and other consulting firms.
Founded in 2025, Pharosyn continuously tracks clinical, regulatory, and commercial sources, including trial data, deals, hiring trends, epidemiology, and social media. It turns this information into structured reports and alerts.
A competitive intelligence director from one of the top-10 biopharmaceutical companies, as cited in a Pharosyn case study, stated that a task that previously took an outside vendor two hours now only takes 15 minutes.
Emphasis on traceability over drug discovery
Pharosyn makes sure every output can be traced back to its source data. This is crucial in pharma, where important commercial decisions rely on trustworthy information.
Established companies in pharmaceutical commercial intelligence, such as GlobalData, Evaluate Pharma, and AlphaSen, primarily build forecasting and competitive intelligence tools using structured data rather than generative AI. New York-based Octozi also raised $3 million in seed funding this year to tackle clinical trial data challenges.
Pharosyn focuses on commercial and portfolio strategy work, which usually moves more slowly than drug discovery and trials and has seen less AI investment so far.
This funding round is part of a busy year for AI investment in pharma. New York’s Solstice raised $21 million in May to speed up marketing approvals. Munich’s Cellbyte got $2.75 million for drug-launch workflows. Cambridge-based Qureight raised $20 million for AI-assisted clinical trials. Moonfire also invested in regulated sectors, including an $8 million investment in London’s Eunice to support audit-ready due diligence.
Mattias Ljungman, founder of Moonfire, added, “Pharosyn’s founders are deeply technical, exceptionally tenacious and ambitious, and determined to be best-in-class globally. They are rare founders who clearly stand out. We could not be more excited to lead this round.”
What the funding pays for
The new funding will go toward hiring engineers and pharmaceutical industry specialists, growing the team beyond its current 11 members.
“It’s about expanding the team, growing quickly, and building an incredible group of engineers and experienced industry professionals. You have to move fast today, or you will die,” Cowley concludes.
